admin

The Municipal Securities Rulemaking Board’s upcoming meeting of its board of directors April 17-18 will focus discussion on its many rule proposals underway. The board will review the public comments they received as part of the request for information on small firms, which saw 22 different firms and groups submit responses. They will also discuss
0 Comments
US Federal Reserve Chair Jerome Powell attends a “Fed Listens” event in Washington, DC, on October 4, 2019. Eric Baradat | AFP | Getty Images A hotter-than-expected consumer price index reading rattled markets Wednesday, but markets are buzzing about an even more specific prices gauge contained within the data — the so-called supercore inflation reading.
0 Comments
Stay informed with free updates Simply sign up to the UK interest rates myFT Digest — delivered directly to your inbox. Cuts in UK interest rates “should still be a way off”, according to one Bank of England policymaker, arguing investors were underestimating the risk that high inflation would linger for longer in Britain than
0 Comments
S&P Global Ratings on Wednesday upgraded its long-term rating on Detroit’s unlimited-tax general obligation debt to investment grade, raising it to BBB from BB-plus. The outlook is stable. The rating agency said the change reflected a stronger financial position and its “increased confidence in the city’s ability to sustain balance within the construct of its
0 Comments
Munis were a touch firmer in spots Tuesday as the primary market ramped up and investors awaited Wednesday’s inflation report to give further guidance on Fed rate cuts. U.S. Treasuries were firmer and equities were mixed at the close. The two-year muni-to-Treasury ratio Tuesday was at 65%, the three-year at 64%, the five-year at 61%,
0 Comments
Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. AstraZeneca’s chief executive Pascal Soriot is “massively underpaid” and deserves a proposed £1.8mn pay rise, according to one of the drugmaker’s top shareholders. The British pharmaceutical company is preparing for a vote on its long-serving
0 Comments